Although BTLA and PDL1 employ distinct phosphatases to suppress T-cell signaling, both of them dampen the TCR and CD28 signaling pathways equally, and thus the inhibitors of both BTLA and PDL1 might be regarded as a combination of immunotherapeutic agents for cancer treatment (54, 55). This evidence concerns the gene CD28 and cancer.